USFDA nod to Bristol Myers Squibb-2seventy bio Abecma for triple-class exposed relapsed or refractory Multiple Myeloma after 2 prior lines of therapy Ruchika Sharma8 April 2024 4:23 PM ISTPrinceton: Bristol Myers Squibb and 2seventy bio, Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved...
Bristol Myers Squibb Reblozyl gets expanded European nod for anemia in lower risk Myelodysplastic Syndromes Ruchika Sharma4 April 2024 2:13 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has expanded approval of Reblozyl (luspatercept) to include...
Bristol Myers Squibb Abecma approved in European Union for triple-class exposed relapsed and refractory multiple myeloma Ruchika Sharma22 March 2024 4:02 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Abecma (idecabtagene vicleucel;...
Bristol Myers Squibb concludes acquisition of Karuna Therapeutics Ruchika Sharma21 March 2024 11:37 AM ISTPrinceton: Bristol Myers Squibb has announced that the Company has successfully completed its acquisition of Karuna Therapeutics, Inc. With the...
Bristol Myers Squibb gets USFDA accelerated nod for Breyanzi as CAR T Cell Therapy for adults with relapsed or refractory chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Susmita Roy15 March 2024 12:32 PM ISTPrinceton: Bristol Myers Squibb has announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of...
USFDA approves Opdivo in combo with Cisplatin and Gemcitabine for first-line treatment of adult patients with metastatic Urothelial Carcinoma: Bristol Myers Squibb Ruchika Sharma9 March 2024 1:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab), in combination...
Bristol Myers Squibb concludes acquisition of RayzeBio Ruchika Sharma27 Feb 2024 1:30 PM ISTPrinceton: Bristol Myers Squibb has announced that it has successfully completed its acquisition of RayzeBio, Inc. With the completion of the...
Bristol Myers Squibb gets EMA Committee positive opinion for Reblozyl for adults with Transfusion-Dependent Anemia due to Low-to Intermediate-Risk Myelodysplastic Syndromes Ruchika Sharma25 Feb 2024 3:30 PM ISTPrinceton: Bristol Myers Squibb has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Bristol Myers Squibb, Immunocore Holdings ink pact to evaluate IMC-F106C, nivolumab combo in registrational Phase 3 first-line advanced cutaneous melanoma trial Ruchika Sharma25 Feb 2024 2:00 PM ISTOxfordshire: Immunocore Holdings plc, a commercial-stage biotechnology company has announced that it has entered into a clinical trial...
USFDA accepts for priority review Bristol Myers Squibb application for Krazati, cetuximab combo for colorectal cancer Ruchika Sharma22 Feb 2024 1:30 PM ISTNew York: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental...
Bristol Myers Squibb application for Augtyro for NTRK-Positive Locally Advanced or Metastatic Solid Tumors accepted by USFDA for priority review Ruchika Sharma15 Feb 2024 11:13 AM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug...
Bristol Myers Squibb concludes acquisition of Mirati Therapeutics Ruchika Sharma26 Jan 2024 12:15 PM ISTThe transaction is expected to be treated as a business combination and to be dilutive to Bristol Myers Squibb's non-GAAP earnings per share by...
